Japanese Bioventure JCR Develops Transplant Cellular Therapy
This article was originally published in PharmAsia News
Executive Summary
Japan's JCR Pharmaceuticals, with the help of Mochida Pharmaceutical, has in two phases of trials, a treatment aimed at reducing the side effects of bone marrow transplants. JCR, a bioventure, has the cellular therapy JR-031 in Phase I and Phase II trials simultaneously. The treatment involves cultured human mesenchymal stem cells taken from the spinal fluid of healthy people and injected into a transplant patient. The work is being done in cooperation with Mochida and JCR expects to complete both sets of trials in 2011. If successful, JR-031 would be Japan's first cellular therapy. (Click here for more - a subscription may be required